Table 1.
Results of initial combination antiviral therapy for chronic hepatitis B
| Groups | Virologic response % | HBeAg clearance % | HBeAg seroconversion % | HBsAg clearance % | ALT normalization % | Drug resistance % | Time (weeks) | Number of patients | References |
|---|---|---|---|---|---|---|---|---|---|
| LAM + ADV | 100 | – | 51 | – | 100 | 0 | 96 | 50 | He et al. [38] |
| LAM | 66 | – | 21 | – | 77 | 34 | 96 | 50 | |
| ADV | 49 | – | 33 | – | 64 | 4 | 96 | 50 | |
| Ldt + ADV | 90.6 | 46.9 | 37.5 | – | 93.8 | 0 | 96 | 32 | Li et al. [39] |
| LAM + ADV | 68.8 | 21.9 | 15.6 | – | 87.5 | 0 | 96 | 32 | |
| Peg-IFN-α-2a + ETV | 100 | 30 | 10 | – | 90 | – | 24 | 20 | Zeng et al. [40] |
| Peg-IFN-α-2a | 30 | 15 | 0 | – | 50 | – | 24 | 20 | |
| ETV | 90 | 20 | 5 | – | 85 | – | 24 | 20 | |
| Peg-IFN-α-2a + ADV | 48.6 | – | 45.7 | – | 60 | – | 96 | 35 | Ma et al. [41] |
| Peg-IFN-α-2a | 34.2 | – | 42.1 | – | 60.5 | – | 96 | 38 | |
| ADV | 12.5 | – | 15 | – | 37.5 | – | 96 | 40 | |
| Peg-IFN-α-2a + LAM | 100 | 80 | 75 | 35 | – | – | 96 | 20 | Cao et al. [37] |
| Peg-IFN-α-2a + ADV | 100 | 76 | 71 | 24 | – | – | 96 | 21 |
– means that no data were reported